The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation
Su Kah Goh, Hongdo Do, Adam Testro, Julie Pavlovic, Angela Vago, Julie Lokan, Robert M Jones, Christopher Christophi, Alexander Dobrovi, Vijayaragavan Muralidhara
Transplantation Direct | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
Background: Assessment of donor-specific cell-free DNA (dscfDNA) in the recipient is emerging as a noninvasive biomarker of organ rejection after transplantation. We previously developed a digital polymerase chain reaction (PCR)-based approach that readily measures dscfDNA within clinically relevant turnaround times. Using this approach, we characterized the dynamics and evaluated the clinical utility of dscfDNA after liver transplantation (LT). Methods: Deletion/insertion polymorphisms were used to distinguish donor-specific DNA from recipient-specific DNA. Posttransplant dscfDNA was measured in the plasma of the recipients. In the longitudinal cohort, dscfDNA was serially measured at days ..View full abstract
This study was supported by Austin Medical Research Foundation, Austin Health; Research Scholarship, Australian and New Zealand Hepatic, Pancreatic & Biliary Association; Foundation of Surgery, Royal Australasian College of Surgeons; Victorian Liver Transplantation Unit, Austin Health; Department of Surgery, The University of Melbourne, Austin Health; and Operational Infrastructure Support Program Funding of the Victorian State Government.